Fig. 3From: Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)Calculation formula of the NAR score. (NAR, neoadjuvant rectal; pN, pathologic nodal stage; cT, clinical tumor stage; pT, pathologic tumor stage.)Back to article page